Education
About Us
Working with TipRanks
Follow Us
BioCardia Inc (BCDA)
NASDAQ:BCDA
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.63Last Year’s EPS
-1.35Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 26, 2025
|% Change Since: -19.61%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong set of trial results with significant reductions in heart failure risks and improvements in quality of life. Financial management showed positive trends with reduced expenses and losses. Despite not meeting the primary endpoint, the data was compelling enough to support ongoing regulatory discussions and future trials. However, the unexpected negative market reaction was a noted concern.Company Guidance
During the BioCardia Year-End 2024 Financial Results and Business Update Conference Call, the company provided several key metrics regarding their ongoing clinical trials and financial status. BioCardia announced the results of the CardiAMP Heart Failure trial, which involved 115 randomized ischemic heart failure patients treated with their lead therapeutic candidate, CardiAMP Cell Therapy (BCD-01). The trial showed a 47% relative risk reduction in cardiac death equivalents, a 16% relative risk reduction in major adverse cardiac events, a 10.5-point improvement in quality of life score, and a 13.9-meter improvement in the 6-minute walk distance test over a 2-year follow-up period. Although the primary endpoint was not met, significant improvements were observed, especially in patients with elevated NTproBNP, achieving a p-value of 0.02 for quality of life. Financially, BioCardia reported a 35% decrease in total expenses to $8.1 million for 2024, with a net loss of $7.9 million and cash and cash equivalents totaling $2.4 million at year-end. The company anticipates modest increases in R&D expenses for 2025 as they advance their therapeutic candidates.Strong CardiAMP Heart Failure Trial Results
The CardiAMP Heart Failure trial showed a 47% relative risk reduction in heart death equivalents and a 16% relative risk reduction in major adverse cardiac events. Quality of life scores improved by 10.5 points, and there was a 13.9-meter improvement in the 6-minute walk distance. The trial also demonstrated improved left ventricular ejection fraction, reduced heart volumes, and reduced cardiac arrhythmias.
Financial Improvements
BioCardia's total expenses decreased by 35% year-over-year to $8.1 million in 2024, driven by a 43% reduction in research and development expenses. The net loss decreased from $11.6 million in 2023 to $7.9 million in 2024.
Regulatory Progress and Future Developments
The CardiAMP cell therapy has an FDA breakthrough designation and discussions with regulatory agencies in the US and Japan are ongoing. The CardiAMP Heart Failure II trial is active with potential for regulatory approval based on the strong data.
---
BCDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BCDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 26, 2025 | $2.55 | $2.68 | +5.10% |
| Nov 13, 2024 | $2.35 | $2.02 | -14.04% |
| Aug 13, 2024 | $2.64 | $2.59 | -1.89% |
| May 14, 2024 | $5.94 | $6.00 | +1.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioCardia Inc (BCDA) report earnings?
BioCardia Inc (BCDA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is BioCardia Inc (BCDA) earnings time?
BioCardia Inc (BCDA) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCDA EPS forecast?
BCDA EPS forecast for the fiscal quarter 2025 (Q1) is -0.63.
---